FIELD: medicine.
SUBSTANCE: before applying substitute hormonal therapy (SHT) on should evaluate antithrombogenic activity of vascular wall in women. For this purpose one should determine quantitative values of ADP-induced aggregation of thrombocytes, activity of antithrombin III in blood and fibrinolytic blood activity both before and after "cuff"-test. Then one should detect the indices calculated as the ratio of mentioned values both before and after carrying out the mentioned test. If mentioned indices are decreased against the norm by 20-40% women should be prescribed to undergo SHT at additional introduction of aspirin and supradin. The method provides prophylaxis of cardio-vascular diseases in this category of female patients due to correcting affected functional activity of vascular endothelium.
EFFECT: higher efficiency of prophylaxis.
1 cl, 1 ex, 4 tbl
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PREDICTING COMPLICATIONS IN CARDIO-VASCULAR SYSTEM AT APPLYING SUBSTITUTION HORMONAL THERAPY | 2004 |
|
RU2248744C1 |
METHOD FOR INDIVIDUAL PREVENTION OF OESTROGEN-DEPENDENT DISEASES IN HEALTHY FEMALES AND FEMALES SUFFERING CARDIOVASCULAR RISK FACTORS AT AGE OF 45-60 YEARS OLD | 2013 |
|
RU2527357C1 |
WAY OF FORECASTING OF OCCURRENCE OF COMPLICATIONS AT WOMEN WITH CLIMACTERIC SYNDROME AGAINST REPLACEABLE HORMONAL THERAPY | 2008 |
|
RU2360610C1 |
METHOD OF PREDICTION OF ANNUAL ANTIOSTEOPOROTIC EFFICIENCY OF MENOPAUSAL HORMONAL THERAPY | 2015 |
|
RU2607304C1 |
METHOD FOR DETECTING ANTIPLATELET DRUG RESISTANCE IN PATIENTS WITH PROGRESSING CEREBRAL ATHEROSCLEROSIS | 2012 |
|
RU2478965C1 |
METHOD OF OPTIMIZATION OF TREATMENT OF WOMEN BY CARDIOTROPIC THERAPY AND HORMONE REPLACEMENT THERAPY FOR ESTROGENDEFICIENCY WITH HYPERTENSION IN THE LATE REPRODUCTIVE PERIOD | 2016 |
|
RU2648470C2 |
MEDICATION WHICH POSSESSES ANTITHROMBOGENIC ACTIVITY | 2010 |
|
RU2440814C1 |
METHOD FOR OPTIMISATION OF MEN CARDIOTROPIC THERAPY AND HORMONE REPLACEMENT THERAPY IN CASE OF ANDROGENODEFICIENCY WITH ARTERIAL HYPERTENSION | 2016 |
|
RU2632449C1 |
AGENT SHOWING ANTIAGGREGANT AND ANTITHROMBOGENIC ACTIVITY | 2010 |
|
RU2453312C1 |
MEDICATION FOR TREATMENT OF CARDIOVASCULAR DISEASES | 2014 |
|
RU2555335C9 |
Authors
Dates
2005-02-20—Published
2004-05-05—Filed